Ads
related to: abbvie email- Investor Resources
Find Financial Reports, Stock Info
And More Resources For Investors.
- Supporting Our Workforce
Embracing Equality & Diversity
Makes Us More Innovative.
- Our Science
See How We Impact Lives.
More Than Developing Medicines.
- Read AbbVie Stories
Read Stories About Our Science,
People, and More Today.
- Investor Resources
mailchimp.com has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. The compound is a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma. [30] In March 2022, AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118.
The contrast between AbbVie's performance and that of the wider market was stark, as the bellwether S&P 500 (SNPINDEX: ^GSPC) sank by a relatively steep 1.5%. Why AbbVie Stock Popped While the ...
AbbVie has been a long-term dividend investor's dream come true since it split from Abbott Laboratories in 2013. 2 No-Brainer Dividend Stocks to Buy With $250 in 2025 Skip to main content
AbbVie (NYSE: ABBV) A large drugmaker that markets therapies targeting autoimmune diseases, cancer, migraine, and more. 3.63%. 17. Pfizer (NYSE: PFE)
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, in the United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products.
In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion. As part of the deal, AbbVie will pay $261.25 per share in a mixture of both cash and AbbVie equity. [6] The merger is expected to close in mid-2015. [7]
AbbVie has offered $31.26 per share in cash, representing a premium of 94.6% to Immuogen stock's last close. Immunogen's shares surged 82% to a near 23-year high of $29.34 in early trading.
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.
Ad
related to: abbvie email